Gerhard Koenig

Gerhard Koenig is the Chief Executive Officer of Augustine Therapeutics, a Belgian-Boston biotechnology company developing highly selective, brain-penetrant HDAC6 inhibitors for neuromuscular, neurodegenerative and cardiometabolic diseases. A neurobiologist by training with more than 30 years in drug development, he has led and co-founded multiple biotechs, including Arkuda Therapeutics, whose portfolio was acquired by Johnson & Johnson, and Quartet Medicine. He stepped up from Executive Chairman to CEO of Augustine in January 2025 as the company moved to enter the clinic, then helped close a large Series A to fund a proof-of-concept trial in Charcot-Marie-Tooth disease.